

David J Farrell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11994878/publications.pdf>

Version: 2024-02-01

146
papers

6,488
citations

50276

46
h-index

82547

72
g-index

146
all docs

146
docs citations

146
times ranked

5246
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Increased Antimicrobial Resistance Among Nonvaccine Serotypes of <i>Streptococcus pneumoniae</i> in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 123-128. | 2.0 | 207 |
| 2 | Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009â€“2012. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 328-334. | 2.5 | 194 |
| 3 | Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009â€“2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 443-448. | 1.8 | 184 |
| 4 | Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6305-6310. | 3.2 | 177 |
| 5 | Novel Mechanism of Resistance to Oxazolidinones, Macrolides, and Chloramphenicol in Ribosomal Protein L4 of the <i>Pneumococcus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3554-3557. | 3.2 | 138 |
| 6 | Trends in antibacterial resistance among <i>Streptococcus pneumoniae</i> isolated in the USA: update from PROTEKT US Years 1â€“4. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2008, 7, 1. | 3.8 | 133 |
| 7 | Antimicrobial activity of ceftolozane/tazobactam tested against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011â€“12). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2713-2722. | 3.0 | 130 |
| 8 | Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1684-1692. | 3.2 | 129 |
| 9 | Assessment of linezolid resistance mechanisms among <i>Staphylococcus epidermidis</i> causing bacteraemia in Rome, Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2329-2335. | 3.0 | 126 |
| 10 | Evaluation of AMPLICOR <i>Neisseria gonorrhoeae</i> PCR Using <i>cppB</i> Nested PCR and 16S rRNA PCR. <i>Journal of Clinical Microbiology</i> , 1999, 37, 386-390. | 3.9 | 126 |
| 11 | Detection of a New <i>cfr</i> -Like Gene, <i>cfr</i> (B), in <i>Enterococcus faecium</i> Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6256-6261. | 3.2 | 124 |
| 12 | Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 533-539. | 2.5 | 123 |
| 13 | Mutation-Driven β -Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible <i>Pseudomonas aeruginosa</i> Isolates from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6844-6850. | 3.2 | 118 |
| 14 | Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Bacteroides fragilis</i> Strains Having Various Resistance Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2390-2394. | 3.2 | 112 |
| 15 | Emergence and Spread of <i>Streptococcus pneumoniae</i> with <i>erm</i> (B) and <i>mef</i> (A) Resistance. <i>Emerging Infectious Diseases</i> , 2005, 11, 851-867. | 4.3 | 108 |
| 16 | Genome-wide dissection of globally emergent multi-drug resistant serotype 19A <i>Streptococcus pneumoniae</i> . <i>BMC Genomics</i> , 2009, 10, 642. | 2.8 | 98 |
| 17 | Increase in <i>Pneumococcus</i> Macrolide Resistance, United States. <i>Emerging Infectious Diseases</i> , 2009, 15, 1260-1264. | 4.3 | 93 |
| 18 | Antimicrobial Susceptibilities of a Worldwide Collection of <i>Stenotrophomonas maltophilia</i> Isolates Tested against Tigecycline and Agents Commonly Used for <i>S. maltophilia</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2735-2737. | 3.2 | 93 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Molecular Analysis of Antimicrobial Resistance Mechanisms in <i>Neisseria gonorrhoeae</i> Isolates from Ontario, Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 703-712. | 3.2 | 93 |
| 20 | Occurrence and molecular characterization of fusidic acid resistance mechanisms among <i>Staphylococcus</i> spp. from European countries (2008). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1353-1358. | 3.0 | 89 |
| 21 | Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates during a 55-Passage Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1177-1181. | 3.2 | 82 |
| 22 | LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3684-3690. | 3.2 | 79 |
| 23 | Molecular Epidemiology of Multiresistant <i>Streptococcus pneumoniae</i> with Both erm (B)- and mef (A)-Mediated Macrolide Resistance. <i>Journal of Clinical Microbiology</i> , 2004, 42, 764-768. | 3.9 | 78 |
| 24 | In Vitro Activities of Telithromycin, Linezolid, and Quinupristin-Dalfopristin against <i>Streptococcus pneumoniae</i> with Macrolide Resistance Due to Ribosomal Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3169-3171. | 3.2 | 78 |
| 25 | In Vitro Activity of Ceftaroline Against Multidrug-Resistant <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> : A Review of Published Studies and the AWARE Surveillance Program (2008-2010). <i>Clinical Infectious Diseases</i> , 2012, 55, S206-S214. | 5.8 | 78 |
| 26 | Linezolid surveillance program results for 2008 (LEADER Program for 2008). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 392-403. | 1.8 | 76 |
| 27 | Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005-2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 465-469. | 2.5 | 76 |
| 28 | Molecular Epidemiology of <i>Staphylococcus epidermidis</i> Clinical Isolates from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4656-4661. | 3.2 | 75 |
| 29 | Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). <i>Journal of Infection</i> , 2014, 69, 266-277. | 3.3 | 75 |
| 30 | Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 53-59. | 2.5 | 75 |
| 31 | Ceftazidime-Avibactam Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolated in U.S. Medical Centers in 2012 and 2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3656-3659. | 3.2 | 74 |
| 32 | Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2933-2940. | 3.2 | 71 |
| 33 | Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin <i>in vitro</i> potency. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3453-3458. | 3.0 | 71 |
| 34 | Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β -Lactamases and Methicillin-Resistant <i>Staphylococcus aureus</i> Carrying Various Staphylococcal Cassette Chromosome <i>mec</i> Types. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4779-4785. | 3.2 | 70 |
| 35 | AWARE Ceftaroline Surveillance Program (2008-2010): Trends in Resistance Patterns Among <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S187-S193. | 5.8 | 68 |
| 36 | Characterization of Global Patterns and the Genetics of Fusidic Acid Resistance. <i>Clinical Infectious Diseases</i> , 2011, 52, S487-S492. | 5.8 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3882-3888. | 3.2 | 62 |
| 38 | Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010â€“2011. <i>Anaerobe</i> , 2014, 28, 120-125. | 2.1 | 61 |
| 39 | <i>In Vitro</i> Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1751-1754. | 3.2 | 59 |
| 40 | Trends in anti-bacterial resistance among <i>Streptococcus pneumoniae</i> isolated in the USA, 2000â€“2003: PROTEKT US years 1â€“3. <i>Journal of Infection</i> , 2005, 51, 355-363. | 3.3 | 58 |
| 41 | Distribution and antibacterial susceptibility of macrolide resistance genotypes in <i>Streptococcus pneumoniae</i> : PROTEKT Year 5 (2003â€“2004). <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 245-249. | 2.5 | 54 |
| 42 | Declining antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998â€“2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 334-336. | 1.8 | 54 |
| 43 | Linezolid resistance in <i>Enterococcus faecium</i> isolated in Ontario, Canada. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 350-353. | 1.8 | 53 |
| 44 | Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011â€“2014). <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 144-150. | 2.5 | 52 |
| 45 | Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among <i>Streptococcus pneumoniae</i> isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, i17-i22. | 3.0 | 50 |
| 46 | CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 393-401. | 1.8 | 48 |
| 47 | The Macrolide Resistance Genes <i>erm</i> (B) and <i>mef</i> (E) Are Carried by Tn 2010 in Dual-Gene <i>Streptococcus pneumoniae</i> Isolates Belonging to Clonal Complex CC271. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4184-4186. | 3.2 | 47 |
| 48 | Activities of Telithromycin against 13,874 <i>Streptococcus pneumoniae</i> Isolates Collected between 1999 and 2003. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1882-1884. | 3.2 | 46 |
| 49 | LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 54-61. | 1.8 | 45 |
| 50 | Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 233-238. | 1.8 | 44 |
| 51 | Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 537-543. | 2.5 | 43 |
| 52 | Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, iii69-iii80. | 3.0 | 43 |
| 53 | In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 531-536. | 2.5 | 42 |
| 54 | Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5547-5551. | 3.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 275-279. | 1.8 | 42 |
| 56 | Age-related genotypic and phenotypic differences in <i>Moraxella catarrhalis</i> isolates from children and adults presenting with respiratory disease in 2001-2002. <i>Microbiology (United Kingdom)</i> , 2008, 154, 1178-1184. | 1.8 | 41 |
| 57 | Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2274-2280. | 3.2 | 41 |
| 58 | Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 459-467. | 1.8 | 39 |
| 59 | Prevalence and Molecular Analysis of Macrolide and Fluoroquinolone Resistance among Isolates of <i>Streptococcus pneumoniae</i> Collected during the 2000-2001 PROTEKT US Study. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4980-4987. | 3.9 | 38 |
| 60 | β-lactamase and antibiotic resistances in a global cross-sectional study of <i>Moraxella catarrhalis</i> from children and adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 91-97. | 3.0 | 38 |
| 61 | In Vitro Activity of Lefamulin Tested against <i>Streptococcus pneumoniae</i> with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4407-4411. | 3.2 | 38 |
| 62 | Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 39-45. | 2.5 | 36 |
| 63 | Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3999-4004. | 3.2 | 35 |
| 64 | Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> Strains Recovered from a Phase IV Clinical Trial for Linezolid versus Vancomycin for Treatment of Nosocomial Pneumonia. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3694-3702. | 3.9 | 34 |
| 65 | The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). <i>Journal of Infection</i> , 2010, 61, 476-483. | 3.3 | 33 |
| 66 | Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 379-381. | 1.8 | 33 |
| 67 | Prevalence and Antibacterial Susceptibility of <i>mef</i> (A)-Positive Macrolide-Resistant <i>Streptococcus pneumoniae</i> over 4 Years (2000 to 2004) of the PROTEKT US Study. <i>Journal of Clinical Microbiology</i> , 2007, 45, 290-293. | 3.9 | 32 |
| 68 | Telithromycin Resistance in <i>Streptococcus pneumoniae</i> Is Conferred by a Deletion in the Leader Sequence of <i>erm</i> (B) That Increases rRNA Methylation. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 435-440. | 3.2 | 32 |
| 69 | Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 498-504. | 3.0 | 32 |
| 70 | Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5393-5399. | 3.2 | 32 |
| 71 | Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and <i>Acinetobacter</i> spp. isolated in US medical centers (2005-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 223-227. | 1.8 | 31 |
| 72 | Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1639-1642. | 3.2 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S181-S186. | 5.8 | 30 |
| 74 | Oritavancin Activity against <i>Staphylococcus aureus</i> Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2921-2924. | 3.2 | 30 |
| 75 | Activity of Debio1452, a FabI Inhibitor with Potent Activity against <i>Staphylococcus aureus</i> and Coagulase-Negative <i>Staphylococcus</i> spp., Including Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2583-2587. | 3.2 | 30 |
| 76 | <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Contemporary <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers by Census Region, 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2537-2541. | 3.2 | 30 |
| 77 | Non-susceptibility trends and serotype distributions among <i>Streptococcus pneumoniae</i> from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, ii87-ii95. | 3.0 | 28 |
| 78 | Activity of ceftaroline and comparator agents tested against <i>Staphylococcus aureus</i> from patients with bloodstream infections in US medical centres (2009-2013). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2053-2056. | 3.0 | 28 |
| 79 | Results from the Solithromycin International Surveillance Program (2014). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3662-3668. | 3.2 | 28 |
| 80 | Quinupristin-Dalfopristin Resistance in <i>Streptococcus pneumoniae</i> : Novel L22 Ribosomal Protein Mutation in Two Clinical Isolates from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2696-2698. | 3.2 | 27 |
| 81 | Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2458-2461. | 3.2 | 27 |
| 82 | Molecular Characterization and Antimicrobial Susceptibility of Fluoroquinolone-Resistant or -Susceptible <i>Streptococcus pneumoniae</i> from Hong Kong. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1433-1435. | 3.2 | 26 |
| 83 | Antibacterial susceptibility among <i>Streptococcus pneumoniae</i> isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, i23-i29. | 3.0 | 26 |
| 84 | Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3263-3270. | 3.2 | 26 |
| 85 | Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible <i>Citrobacter</i> spp., <i>Enterobacter</i> spp., <i>Serratia marcescens</i> , and <i>Pseudomonas aeruginosa</i> from United States medical centers (2011-2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 389-394. | 1.8 | 25 |
| 86 | <i>In vitro</i> activity of linezolid as assessed through the 2013 LEADER surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 283-289. | 1.8 | 25 |
| 87 | The Role of <i>Ureaplasma urealyticum</i> in Adverse Pregnancy Outcome. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1997, 37, 45-51. | 1.0 | 24 |
| 88 | Antimicrobial Susceptibility of Respiratory Tract Pathogens in Japan During PROTEKT Years 1-5 (1999-2004). <i>Microbial Drug Resistance</i> , 2008, 14, 109-117. | 2.0 | 24 |
| 89 | Noninvasive <i>Streptococcus pneumoniae</i> Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5595-5601. | 3.2 | 24 |
| 90 | Telavancin <i>In Vitro</i> Activity against a Collection of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates, Including Resistant Subsets, from the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1811-1814. | 3.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 93-97. | 1.8 | 22 |
| 92 | Activity of ceftobiprole against methicillin-resistant <i>Staphylococcus aureus</i> strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 323-327. | 2.5 | 22 |
| 93 | Activity of Fusidic Acid Tested against <i>Staphylococci</i> Isolated from Patients in U.S. Medical Centers in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3827-3831. | 3.2 | 22 |
| 94 | JNJ-Q2, a New Fluoroquinolone with Potent <i>In Vitro</i> Activity against <i>Staphylococcus aureus</i> , Including Methicillin- and Fluoroquinolone-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3631-3634. | 3.2 | 21 |
| 95 | Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007–2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 113-117. | 1.8 | 21 |
| 96 | Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of <i>Streptococcus pneumoniae</i> from U.S. Medical Centers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2468-2471. | 3.2 | 21 |
| 97 | Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 702-706. | 3.2 | 21 |
| 98 | Rifaximin in the Treatment of Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 205-211. | 2.2 | 20 |
| 99 | Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 837-842. | 2.0 | 20 |
| 100 | Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13): Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 276-278. | 3.0 | 20 |
| 101 | Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) <i>Streptococcus pneumoniae</i> Serotypes in the United States, 2011-2012: Ceftaroline Remains Active <i>In Vitro</i> among β -Lactam Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4923-4927. | 3.2 | 19 |
| 102 | Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010–2012). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 449-456. | 1.8 | 19 |
| 103 | Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative <i>Staphylococcus</i> causing infection in US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 80-84. | 1.8 | 19 |
| 104 | ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. <i>Journal of Chemotherapy</i> , 2012, 24, 328-337. | 1.5 | 18 |
| 105 | <i>Streptococcus pyogenes</i> Isolates with High-Level Macrolide Resistance and Reduced Susceptibility to Telithromycin Associated with 23S rRNA Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 817-818. | 3.2 | 17 |
| 106 | Susceptibility of <i>Klebsiella</i> spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006–2009). <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 174-175. | 2.5 | 16 |
| 107 | Ceftaroline Potency Among 9 US Census Regions: Report From the 2010 AWARE Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S194-S205. | 5.8 | 16 |
| 108 | Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 78-84. | 1.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). International Journal of Antimicrobial Agents, 2016, 47, 495-499. | 2.5 | 16 |
| 110 | Heterogeneous Macrolide Resistance and Gene Conversion in the Pneumococcus. Antimicrobial Agents and Chemotherapy, 2006, 50, 359-361. | 3.2 | 15 |
| 111 | Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Annals of Clinical Microbiology and Antimicrobials, 2007, 6, 7. | 3.8 | 15 |
| 112 | Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003–2004). Diagnostic Microbiology and Infectious Disease, 2009, 63, 302-308. | 1.8 | 15 |
| 113 | <i>In Vitro</i> Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea and <i>Clostridium difficile</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 992-996. | 3.2 | 15 |
| 114 | Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagnostic Microbiology and Infectious Disease, 2013, 75, 86-88. | 1.8 | 15 |
| 115 | <i>In Vitro</i> Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-clAI Study. Antimicrobial Agents and Chemotherapy, 2016, 60, 666-668. | 3.2 | 15 |
| 116 | Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of <i>mecA</i> Dropout Mutants. Journal of Clinical Microbiology, 2016, 54, 204-207. | 3.9 | 15 |
| 117 | Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009–2013). Journal of Global Antimicrobial Resistance, 2015, 3, 161-165. | 2.2 | 14 |
| 118 | Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 2558-2563. | 3.2 | 13 |
| 119 | The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2005, 56, 795-797. | 3.0 | 12 |
| 120 | Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. International Journal of Antimicrobial Agents, 2012, 39, 321-325. | 2.5 | 12 |
| 121 | Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. Surgical Infections, 2016, 17, 443-447. | 1.4 | 12 |
| 122 | Ureaplasma Urealyticum Chorioamnionitis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1994, 34, 477-479. | 1.0 | 11 |
| 123 | In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagnostic Microbiology and Infectious Disease, 2016, 86, 66-69. | 1.8 | 11 |
| 124 | In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagnostic Microbiology and Infectious Disease, 2011, 69, 275-279. | 1.8 | 10 |
| 125 | Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004). International Journal of Antimicrobial Agents, 2007, 30, 546-550. | 2.5 | 9 |
| 126 | Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. Journal of Chemotherapy, 2016, 28, 83-88. | 1.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Surveillance of JNJ-Q2 activity tested against <i>Staphylococcus aureus</i> and beta-hemolytic streptococci as a component of the 2010 sentry antimicrobial surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 415-420. | 1.8 | 8 |
| 128 | Surveillance of antimicrobial resistance in contemporary clinical isolates of <i>Bordetella pertussis</i> in Ontario, Canada. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 82-84. | 2.5 | 8 |
| 129 | <i>In Vitro</i> Activity of RX-P873 against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2280-2285. | 3.2 | 8 |
| 130 | Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2727-2730. | 3.9 | 8 |
| 131 | Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 28-32. | 2.2 | 8 |
| 132 | Urinary screening for neisseria gonorrhoeae in asymptomatic individuals from queensland, australia: an evaluation using three nucleic acid amplification methods. <i>Pathology</i> , 2001, 33, 204-205. | 0.6 | 7 |
| 133 | Assessment of the efficacy of telithromycin simulating human exposures against <i>S. pneumoniae</i> with ribosomal mutations in a murine pneumonia model. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 530-534. | 2.5 | 6 |
| 134 | Ceftaroline activity tested against viridans group streptococci from US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 232-235. | 1.8 | 6 |
| 135 | Neonatal Infection Due to <i>Haemophilus Influenzae</i> Biotype IV. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1995, 35, 102-103. | 1.0 | 5 |
| 136 | Comparison of PCR/nucleic acid hybridization and EIA for the detection of <i>Chlamydia trachomatis</i> in different populations in a regional centre. <i>Pathology</i> , 1996, 28, 74-79. | 0.6 | 5 |
| 137 | Multilocus Sequence Typing of <i>Mycobacterium xenopi</i> . <i>Journal of Clinical Microbiology</i> , 2014, 52, 3973-3977. | 3.9 | 5 |
| 138 | Genotypic Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole. <i>Microbial Drug Resistance</i> , 2016, 22, 53-58. | 2.0 | 5 |
| 139 | Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 3888-3890. | 3.9 | 4 |
| 140 | Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 36-39. | 2.2 | 3 |
| 141 | Short-Read Whole-Genome Sequencing for Laboratory-Based Surveillance of <i>Bordetella pertussis</i> . <i>Journal of Clinical Microbiology</i> , 2017, 55, 1446-1453. | 3.9 | 3 |
| 142 | Activity of JNJ-Q2 against <i>Staphylococcus aureus</i> isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 73-74. | 1.8 | 2 |
| 143 | Oritavancin Activity Tested against Molecularly Characterized <i>Staphylococci</i> and <i>Enterococci</i> Displaying Elevated Linezolid MIC Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3817-3820. | 3.2 | 2 |
| 144 | Molecular Analysis of Antimicrobial Resistance Mechanisms in <i>Neisseria gonorrhoeae</i> Isolates from Ontario, Canada. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 632-632. | 3.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Comparison of BD Max StaphSR and BD Max MRSA <i>XT</i> for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States. Journal of Clinical Microbiology, 2016, 54, 1668-1669. | 3.9 | 1 |
| 146 | Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology. International Journal of Antimicrobial Agents, 2005, 26, 331-334. | 2.5 | 0 |